Kardigan, Inc. is a clinical-stage precision therapeutics company. It is developing medicines that target the root cause of specific cardiovascular diseases where no approved treatments exist. Its pipeline of products includes Danicamtiv, Ataciguat and Tonlamarsen. Danicamtiv is an investigational oral cardiac atrial and ventricular myosin activator for the treatment of genetic dilated cardiomyopathy caused by pathogenic variants in myosin heavy chain 7 (MYH7) and titin, the common sarcomeric gene variants. Ataciguat is an investigational oral, once-daily soluble guanylate cyclase activator aimed at slowing the progression of calcific aortic valve stenosis in patients with moderate diseases. Tonlamarsen is an investigational liver-directed antisense oligonucleotide administered once-monthly via subcutaneous injection, targeting hepatic angiotensinogen for the management of blood pressure in acute severe hypertension post-hospitalization. Prolaio is a clinical intelligence platform.
BörsenkürzelKARD
Name des UnternehmensKardigan Inc
IPO-datumJun 18, 2026
CEOGianakakos (Tassos Anastasios)
Anzahl der mitarbeiter420
WertpapierartOrdinary Share
GeschäftsjahresendeJun 18
Addresse506 Carnegie Center Drive, Suite 201
StadtPRINCETON JUNCTION
BörseNASDAQ OMX - NASDAQ BASIC
LandUnited States of America
Postleitzahl08540
Telefon14155733220
Websitehttp://www.kardigan.bio
BörsenkürzelKARD
IPO-datumJun 18, 2026
CEOGianakakos (Tassos Anastasios)